tiragolumabVibostolimabpembrolizumab
…55 with a larger coverage area than another anti-TIGIT antibody tiragolumab, consistent with surface plasmon resonance analysis, though mou…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 415 of 2459ARDShigh-flow nasal oxygenacute respiratory distress syndromeSuzhouHaematopoietic reconstitution
…ong the 1024 patients, 58 (5.6%) died within 1 year after HSCT. ARDS during haematopoietic reconstitution occurred in 45 patients (4…
COVID-19pyelonephritisinfluenzapneumoniasepticaemiasuppressive therapySuppressive antibiotic therapyUTIs
…), followed by septicaemia (HR, 1.34 (95% CI 1.13 to 1.59)) and COVID-19 (HR 1.23 (95% CI 1.01 to 1.50)).Conclusions Suppressive antibio…
tuberculosispreventive treatmentIGRA
…sed at 0 and 3 months for contact screening, but half of future tuberculosis cases might be missed. Follow-on interferon-gamma release assay…
Iscalimabsystemic lupus erythematosusNCT03610516LNCFZ533
…t improvement in proteinuria (UPCR) in patients with active LN. Iscalimab was generally well tolerated with the exception of a few severe…
bisoprololAtrioventricular (AV) nodal diseasehypertrophic cardiomyopathyBeta-blockersatrial fibrillationHCM
…tricular standstill. This progression was likely exacerbated by bisoprolol, which slowed AV conduction in the setting of pre-existing firs…
adenosineNew Cross Hospitalperipheral vascular diseasecoronary stenosisatrial fibrillationdiabetes mellitushypertensionchronic kidney diseaseMI
…cance of a coronary stenosis but requires the administration of adenosine. However, resting full-cycle ratio (RFR) is a newer, non-hypera…
93.7%
Calderdale Royal HospitalSmall vessel diseaseIn-stent Restenosisin-stent restenosis (ISR)Drug Eluting StentIschaemic Heart DiseaseChronic kidney diseaseDrug Eluting Stent (DES)Diabetes mellitus78DES
…ural data of all DCB deployed between March 2022 to May 2024 at Calderdale Royal Hospital, was collected from patient’s hospital electronic health record…
96.1%
heart failureEQ-5DNICEFDAOxford University PressNCT06334822
…ity-of-life impact of both major and minor healthcare events in heart failure patients. The findings indicate that while hospitalisations hav…
HFpEFHFrEFAKI on CKDDigoxin DHPCOPD
…th significant reductions observed in the compensated state for HFpEF (to 10.8±2.8m/s, p<0.001) and AKI on CKD (to 10.8±3.4m/s, p=0.0…